P694: Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrenceECCO’23 CopenhagenYear: 2023
Authors: Mañosa CiriaPhD, M.(1,2)*;Oller, B.(1);Garcia-Planella, E.(3);Guardiola, J.(4);Cañete, F.(1,2);Gonzalez Muñoza, C.(3);Camps, B.(4);Calafat, M.(1,2);Domènech, E.(2,5);
(1)Hospital Universitari Germans Trias I Pujol, Gastroenterology, Badalona, Spain;(2)Ciberehd, Ciberehd, Madrid, Spain;(3)Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(4)Hospital de Bellvitge, Gastroenterology, L'Hospitalet de LLobregat, Spain;(5)Hospital Universitari Germain Trias i Pujol, Gastroenterology, Badalona, Spain;
P695: Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: McShane, C.(1)*;Varley, R.(2);Fennessy, A.(3);Campion, J.(4);Ring, E.(5);Kelly, O.(5);Slattery, E.(4);Doherty, G.(6);McCarthy, J.(2);Kevans, D.(7);
(1)St James's Hospital, Department of Gastroenterology, Dublin, Ireland;(2)Mercy University Hospital, Department of Gastroenterology, Cork, Ireland;(3)St Vincent's University Hospital, Department of Gastroenterology and Colorectal Disease, Dublin, Ireland;(4)Galway University Hospital, Department of Gastroenterology, Galway, Ireland;(5)Connolly Hospital, Department of Gastroenterology, Dublin, Ireland;(6)Department of Gastroenterology and Colorectal Disease, Department of Gastroenterology, Dublin, Ireland;(7)St. James's Hospital, Department of Gastroenterology, Dublin, Ireland;INITIative Network
P696: Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.C.(3);Adsul, S.(5);Freire, M.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.(7);Moran, G.W.(8,9);Sebastian, S.(10,11);Travis, S.(12);Vermeire, S.(13);Sandborn, W.J.(14);D'Haens, G.R.(15); Feagan, B.G.(1,2,3);
(1)University of Western Ontario, Department of Medicine- Division of Gastroenterology, London, Canada;(2)University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada;(3)Alimentiv Inc., Medical Research and Development, London, Canada;(4)University of Western Ontario, Robarts Research Institute- Schulich School of Medicine and Dentistry, London, Canada;(5)Takeda Pharmaceuticals, Medical, Cambridge, United States;(6)Inserm NGERE U1256- University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(7)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(8)University of Nottingham, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham, United Kingdom;(9)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(10)Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom;(11)Hull York Medical School, School of Health & Life Sciences, Hull, United Kingdom;(12)University of Oxford, Kennedy Institute and Biomedical Research Centre, Oxford, United Kingdom;(13)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(14)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(15)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;on behalf of the VERDICT Study Group
P697: De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.ECCO’23 CopenhagenYear: 2023
Authors: Arenas, A.(1,2,3)*;Moreta, M.J.(4);Ordás, I.(1,4);Fernández-Clotet, A.(1,4);Caballol, B.(1,4);Gallego, M.(1,4);Vara, A.(1,4);Barastegui, R.(1,4);Giner, A.(1,4);Prieto, C.(1,4);Masamunt, M.C.(1,4);Ricart, E.(1,4);
(1)Hospital Clínic, Inflammatory Bowel Disease Unit, Barcelona, Spain;(2)Complejo Asistencial Dr. Sótero del Río, Unidad de Gastroenterología, Santiago, Chile;(3)Facultad de Medicina Clínica Alemana-Universidad del Desarrollo, Gastroenterología, Santiago, Chile;(4)Hospital Clínic, Gastroenterology, Barcelona, Spain;
P698: Role of an exclusion diet (reduced disaccharides, saturated fats, emulsifiers, red and ultraprocessed meats) in maintaining the remission of chronic inflammatory bowel diseases in adultsECCO’23 CopenhagenYear: 2023
Authors: Preda, C.M.(1)*;Istratescu, D.(2);Manuc, T.(2);Nitescu, M.(3);Louis, E.(4);Manuc, M.(2);Stroie, T.(2);Diculescu, M.(2);
(1)Clinical Institute Fundeni, Department of Gastroenterology and Hepatology, Bucharest, Romania;(2)Clinical Fundeni Institute, Department of Gastroenterology and Hepatology, Bucharest, Romania;(3)UMF „Carol Davila” National Institute for Infectious Diseases Prof. Dr. MateiBals-, Department of Infectious Diseases, Bucharest, Romania;(4)CHU de Liege, Department of Gastroenterology, Liege, Belgium;
P699: Ustekinumab therapy after biologic failure in patients with Crohn's Disease – A real-world single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Majumder, S.(1,2,3)*;Bazarova, A.(4);Lorenzo Parigi, T.(1,3); Love , M.(5);Davis , J.(3);Ghosh, S.(6); Iacucci , M.(1,3,7);N. Shivaji, U.(1,3,7);
(1)University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)India Institute- University of Birmingham, Fellowship, Birmingham, United Kingdom;(3)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(4)Institute for Biological Physics University of Cologne, Biological Physics, Cologne, Germany;(5)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Gastroenterology, United Kingdom;(6)College of Medicine and Health- University College Cork, APC Microbiome, Cork, Ireland;(7)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;
P700: Perceptions towards established and emerging dietary therapies for Crohn's disease management among the adult patients: results from a questionnaire surveyECCO’23 CopenhagenYear: 2023
Authors: Jatkowska, A.(1);White, B.(1);Jaskolski, P.(1);Brownson, E.(2);Clowe, J.(2);Seenan, J.P.(2);Gerasimidis, K.(1)*;MacDonald, J.(2);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
P701: A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion intervalECCO’23 CopenhagenYear: 2023
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1)*;
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P702: Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Spela, P.(1)*;Hanžel, J.(2);Smrekar, N.(2);Koželj, M.(2);Drobne, D.(2);Kurent, T.(2);Štabuc, B.(2);Novak, G.(2);
(1)UKC Ljubljana, Departement for gastroenterology and hepatology, Ljubljana, Slovenia;(2)University Medical Centre Ljubljana, Departement for gastroentrerology and hepatology, Ljubljana, Slovenia;
P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver diseaseECCO’23 CopenhagenYear: 2023
Authors: Mitrovic, M.(1)*;Marković, S.(1);Kalaba, A.(2);Zarić, D.(1);Kralj, Đ.(1);Milić, A.(2);Svorcan, P.(1);
(1)University Medical Center Zvezdara, Department of Gastroenterology, Belgrade, Serbia;(2)University Medical Center Zvezdara, Departement of Gastroenterology, Belgrade, Serbia;
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomesECCO’23 CopenhagenYear: 2023
Authors: Nowell, E.(1);Laird, S.(1);Bailey, E.(1);Brownson, E.(1)*;Saunders, J.(1);Seenan, J.P.(1);Smith, G.(1);Macdonald, J.(1);
(1)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;
P706: Monitoring asymptomatic patients with Crohn's disease: the role of intestinal ultrasoundECCO’23 CopenhagenYear: 2023
Authors: Dussias, N.(1)*;Melotti, L.(1);Mazzotta, E.(1);Decorato, A.(1);Vanigli, N.(1);Rizzello, F.(1);Gionchetti, P.(1);
(1)IRCCS Azienda Ospedaliero-Universitaria Policlinico S. Orsola - Malpighi, Department of Medical and Surgical Sciences, Bologna, Italy;
P707: Using urgent small bowel ultrasound (SBUS) as a tool for decision-making in patients with inflammatory bowel disease (IBD): retrospective analysis of United Kingdom (UK) patients' outcome.ECCO’23 CopenhagenYear: 2023
Authors: Lehmann, A.(1)*;Nandra, G.(2);Power, N.(2);Lindsay, J.O.(1);
(1)Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(2)Barts Health NHS Trust, Radiology, London, United Kingdom;James Oliver Lindsay
P708: Post-COVID-19 and Quality of Life in Patients with Immune Mediated Inflammatory DiseasesECCO’23 CopenhagenYear: 2023
Authors: Schlosser, T.(1)*;Krasselt , M.(2);Elsing, L.(1);Hecker, M.(1);Holler, B.(1);Hoffmeister, A.(1);
(1)University Medical Centre Leipzig, Department of Oncology- Gastroenterology- Hepatology- Pulmonology and Infectious Diseases- Division of Gastroenterology, Leipzig, Germany;(2)University Medical Centre Leipzig, Department of Endocrinology- Nephrology and Rheumatology- Division of Rheumatology, Leipzig, Germany;
P709: Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn's disease of the small intestineECCO’23 CopenhagenYear: 2023
Authors: Viazis, N.(1)*;Koustenis, K.(1);Veretanos, C.(1);Mountaki, A.(1);Almpani, F.(1);Tsatsa, A.(1);Trikola, A.(1);Beka, H.(1);Arvanitis, K.(1);Georgiadi, T.(1);Nousias, G.(1);Mylonas, I.(1);Kozompoli, D.(1);Paparizou, N.(1);Karaouzas, L.(1);Papastergiou, V.(1);Archavlis, E.(1);Mela , M.(1);Christidou, A.(1);Varytimiadis , K.(1);Hatzievangelinou, C.(1);Katopodi, K.(1);Vienna, E.(1);Mantzaris, G.(1);
(1)Evangelismos Hospital, Gastroenterology, Athens, Greece;
P710: Changes of gut microbiome after anti-TNF-α therapy and the prediction of clinical remission in patients with active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: ShinShin, S.(1)*;Oh, H.N.(2);Moon, J.M.(1);Joo, H.J.(1);Sul, W.J.(2);Choi, C.H.(1);
(1)Chung-Ang University College of Medicine, Department of Internal medicine, Seoul, Korea- Republic Of;(2)Chung-Ang University, Department of Systems Biotechnology, Anseong, Korea- Republic Of;
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.ECCO’23 CopenhagenYear: 2023
Authors: Yeo, G.D.D.(1)*;Qui, M.(2);Pak, W.C.W.(1);Tan, C.K.(3);Tay, S.W.(1);Lim, C.T.T.(1);Tan, T.K.M.(1);Ong, W.C.(4);Lim, T.G.(4);Ng, Y.T.V.(4);Wong, S.Y.A.(4);Salazar, E.(1);
(1)Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Duke-NUS Medical School, Programme in Emerging Infections Disease, Singapore, Singapore;(3)Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(4)Singapore General Hospital, Department of Pharmacy, Singapore, Singapore;
P713: Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Gonzalez Vivo, M.(1,2)*;Carballo Martinez, N.(2,3);Padulles Zamora, N.(4);Colominas Gonzalez, E.(2,3);Murciano Gonzalo, F.(1);Abril Rodriguez, L.(1);Marquez-Mosquera, L.(1,2);
(1)Hospital del Mar, Gastroenterology department, Barcelona, Spain;(2)IMIM, Hospital del Mar Medical Research Institute, Barcelona, Spain;(3)Hospital del Mar, Pharmacy department, Barcelona, Spain;(4)Hospital Universitari de Bellvitge, Pharmacy department, L'Hospitalet de Llobregat, Spain;
